Federal Register / Vol. 87, No. 30 / Monday, February 14, 2022 / Notices 8265 

contained the anabolic steroid 

Methyldienolone, a controlled 

substance prohibited under the Designer 

Steroid Act, 21 U.S.C. 802(41), which 

Mr. Parks also caused to be imported 

into the United States. Mr. Parks worked 

with others to conceal the importation 

of these and other unapproved drugs as 

they were disguised and misdeclared as 

articles of food, specifically ‘‘biscuit mix 

powder,’’ ‘‘corn powder,’’ ‘‘grain mix 

powder,’’ ‘‘bread mix powder,’’ and 

‘‘milk tea powder.’’ Mr. Parks then 

included these drug active ingredients 

in MedFitRX products, which were 

unapproved drugs that he introduced 

and delivered for introduction into 

interstate commerce. Mr. Parks 

knowingly marketed these MedFitRX 

products as ‘‘dietary supplements’’ and 

‘‘sports supplements’’ to create the 

impression they were safe and legal to 

use, and otherwise intentionally failed 

to include certain drug active 

ingredients on the product labels. 

As a result of this conviction, FDA 

sent Mr. Parks, by certified mail, on 

October 12, 2021, a notice proposing to 

debar him for a 5-year period from 

importing or offering for import any 

article of food or drug into the United 

States. The proposal was based on a 

finding under section 306(b)(1)(C) and 

(b)(3)(C) of the FD&C Act that Mr. Parks’ 

felony conviction of distribution of an 

unapproved new drug with the intent to 

defraud and mislead constitutes 

conduct relating to the importation into 

the United States of an article of food 

and any drug or controlled substance 

because Mr. Parks illegally imported 

unapproved drugs into the United 

States, working with others to disguise 

and misdeclare them as articles of food, 

and then distributed those unapproved 

drugs to consumers in the United States, 

marketing them as ‘‘dietary 

supplements’’ and ‘‘sports 

supplements.’’ In proposing a 

debarment period, FDA weighed the 

considerations set forth in section 

306(c)(3) of the FD&C Act that it 

considered applicable to Mr. Parks’ 

offense, and concluded that the felony 

offense warranted the imposition of a 5- 

year period of debarment. 

The proposal informed Mr. Parks of 

the proposed debarment and offered 

him an opportunity to request a hearing, 

providing him 30 days from the date of 

receipt of the letter in which to file the 

request, and advised him that failure to 

request a hearing constituted a waiver of 

the opportunity for a hearing and of any 

contentions concerning this action. Mr. 

Parks received the proposal and notice 

of opportunity for a hearing on October 

18, 2021. Mr. Parks failed to request a 

hearing within the timeframe prescribed 

by regulation and has, therefore, waived 

his opportunity for a hearing and 

waived any contentions concerning his 

debarment (21 CFR part 12). 

II. Findings and Order 

Therefore, the Assistant 

Commissioner, Office of Human and 

Animal Food Operations, under section 

306(b)(1)(C) and (b)(3)(C) of the FD&C 

Act, under authority delegated to the 

Assistant Commissioner, finds that Mr. 

Brian Michael Parks has been convicted 

of a felony under Federal law for 

conduct relating to the importation into 

the United States of an article of food 

and of a drug or controlled substance, 

and that he is subject to a 5-year period 

of debarment. 

As a result of the foregoing finding, 

Mr. Parks is debarred for a period of 5 

years from importing or offering for 

import articles of food or any drug or 

controlled substances into the United 

States, applicable (see DATES). Pursuant 

to section 301(cc) of the FD&C Act, the 

importing or offering for import into the 

United States of an article of food or of 

any drug or controlled substance by, 

with the assistance of, or at the direction 

of Mr. Parks is a prohibited act. 

Any application by Mr. Parks for 

termination of debarment under section 

306(d)(1) of the FD&C Act should be 

identified with Docket No. FDA–2021– 

N–0304 and sent to the Dockets 

Management Staff (see ADDRESSES). The 

public availability of information in 

these submissions is governed by 21 

CFR 10.20. 

Publicly available submissions will be 

placed in the docket and will be 

viewable at https://www.regulations.gov 

or at the Dockets Management Staff (see 

ADDRESSES) between 9 a.m. and 4 p.m., 

Monday through Friday, 240–402–7500. 

Dated: February 8, 2022. 

Lauren K. Roth, 

Associate Commissioner for Policy. 

[FR Doc. 2022–03098 Filed 2–11–22; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Meeting of the Advisory Committee on 

Infant and Maternal Mortality (Formerly 

the Advisory Committee on Infant 

Mortality) 

AGENCY: Health Resources and Services 

Administration (HRSA), Department of 

Health and Human Services. 

ACTION: Notice. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, this 

notice announces that the Advisory 

Committee on Infant and Maternal 

Mortality (ACIMM or Committee) has 

scheduled a public meeting. Information 

about ACIMM and the agenda for this 

meeting can be found on the ACIMM 

website at https://www.hrsa.gov/ 

advisory-committees/infant-mortality/ 

index.html. 

DATES: March 15, 2022, 12:00 p.m. to 

4:00 p.m. Eastern Time and March 16, 

2022, 12:00 p.m. to 4:00 p.m. Eastern 

Time. 

ADDRESSES: This meeting will be held 

virtually via webinar. The webinar link 

and log-in information will be available 

at the ACIMM website before the 

meeting: https://www.hrsa.gov/advisorycommittees/infant-mortality/index.html. 

FOR FURTHER INFORMATION CONTACT: 

Anne Leitch, Maternal and Child Health 

Bureau, HRSA, 5600 Fishers Lane, 

Rockville, Maryland 20857; 301–443– 

1321; or SACIM@hrsa.gov. 

SUPPLEMENTARY INFORMATION: ACIMM is 

authorized by section 222 of the Public 

Health Service Act (42 U.S.C. 217a), as 

amended. The Committee is governed 

by provisions of Public Law 92–463, as 

amended, (5 U.S.C. App. 2), which sets 

forth standards for the formation and 

use of Advisory Committees. 

The ACIMM advises the Secretary of 

Health and Human Services (Secretary) 

on department activities, partnerships, 

policies, and programs directed at 

reducing infant mortality, maternal 

mortality and severe maternal 

morbidity, and improving the health 

status of infants and women before, 

during, and after pregnancy. The 

Committee provides advice on how to 

coordinate federal, state, local, tribal, 

and territorial governmental efforts 

designed to improve infant mortality, 

related adverse birth outcomes, and 

maternal health, as well as influence 

similar efforts in the private and 

voluntary sectors. The Committee 

provides guidance and 

recommendations on the policies, 

programs, and resources required to 

address the disparities and inequities in 

infant mortality, related adverse birth 

outcomes and maternal health 

outcomes, including maternal mortality 

and severe maternal morbidity. With its 

focus on underlying causes of the 

disparities and inequities seen in birth 

outcomes for women and infants, the 

Committee advises the Secretary on the 

health, social, economic, and 

environmental factors contributing to 

the inequities and proposes structural, 

policy, and/or systems level changes. 


jspears on DSK121TN23PROD with NOTICES1
8266 Federal Register / Vol. 87, No. 30 / Monday, February 14, 2022 / Notices 

The agenda for the March 15–16, 

2022, meeting is being finalized and 

may include the following topics: 

Federal program updates; COVID–19 

updates; race-concordant care, health of 

indigenous mothers and babies; and, the 

impact of violence on infant and 

maternal mortality. Agenda items are 

subject to change as priorities dictate. 

Refer to the ACIMM website listed 

above for any updated information 

concerning the meeting. 

Members of the public will have the 

opportunity to provide written or oral 

comments. Requests to submit a written 

statement or make oral comments to 

ACIMM should be sent to Anne Leitch 

using the email address above at least 3 

business days prior to the meeting. 

Public participants may submit written 

statements in advance of the scheduled 

meeting by emailing SACIM@hrsa.gov. 

Oral comments will be honored in the 

order they are requested and may be 

limited as time allows. 

Individuals who plan to attend and 

need special assistance or some 

reasonable accommodation should 

notify Anne Leitch at the contact 

information listed above at least 10 

business days prior to the meeting. 

Maria G. Button, 

Director, Executive Secretariat. 

[FR Doc. 2022–03027 Filed 2–11–22; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Health Security Strategy 

AGENCY: Office of the Assistant 

Secretary for Preparedness and 

Response (ASPR), Department of Health 

and Human Services (HHS). 

ACTION: Request for information. 

SUMMARY: The Office of the Assistant 

Secretary for Preparedness and 

Response (ASPR), within the U.S. 

Department of Health and Human 

Services (HHS), is soliciting public 

comment regarding national health 

security threats, challenges, and 

promising practices to help inform the 

development of the 2023–2026 National 

Health Security Strategy (NHSS). Since 

2006, Congress has required the 

Secretary of HHS to develop and submit 

a 4-year NHSS and implementation plan 

that describe ‘‘potential emergency 

health security threats and identify the 

process to be prepared to identify and 

respond to such threats.’’ The 

quadrennial NHSS is a key U.S. 

Government vehicle for advancing 

public health and medical emergency 

capabilities, and serves as a tool to 

address priority threats, measure 

progress, identify gaps, and focus action 

to implement national health security 

capabilities. 

DATES: Comments must be received by 

March 11, 2022. 

ADDRESSES: Comments must be 

submitted electronically via email to the 

following email address: NHSS@

hhs.gov. 

Instructions: Emails to NHSS@hhs.gov 

in response to this announcement 

should include ‘2023–2026 NHSS 

comments’ in the subject line. 

Responses to the Request for 

Information may be placed in the body 

of the email or in an attachment to the 

email using a standard document 

format. 

Request for Information: HHS/ASPR 

is preparing to draft the 2023–2026 

NHSS. To help inform this strategy, 

HHS/ASPR is soliciting public comment 

regarding health security threats, 

challenges, and promising practices that 

may warrant being addressed in the 

2023–2026 NHSS. We invite your 

response to the following questions. 

Please note that you are not limited to 

the questions below and we welcome 

additional feedback. 

• What are the most critical national 

health security threats and public health 

and medical preparedness, response, 

and recovery challenges that warrant 

increased attention over the next five 

years? 

• What medium-term and long-term 

(i.e., over next five years) actions should 

be taken to mitigate these challenges at 

the federal government and/or state, 

local, tribal, and territorial level? 

• What public health and medical 

preparedness, response, and recovery 

opportunities or promising practices 

should be capitalized on over the next 

five years? 

Disclaimer and Important Notes: This 

notice is intended for planning purposes 

and does not constitute a formal 

agreement that information from public 

responses will be included in the 2023– 

2026 NHSS. 

FOR FURTHER INFORMATION CONTACT: 

Darrin Donato, Chief, Domestic Policy 

Branch, Division of Policy, Office of 

Strategy, Policy, Planning, and 

Requirements, ASPR, HHS, Washington, 

DC, NHSS@hhs.gov. 

Dawn O’Connell, 

Assistant Secretary for Preparedness and 

Response. 

[FR Doc. 2022–03046 Filed 2–11–22; 8:45 am] 

BILLING CODE 4150–37–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review Amended; 

Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Biomedical Sensing, 

Measurement and Instrumentation 

Study Section, March 10–11, 2022, 9:30 

a.m. to 7:00 p.m., which was published 

in the Federal Register on February 08, 

2022, 87 FR 7194, FR DOC #2022– 

02598. 

This meeting is being amended to 

change the Contact Person from Yuanna 

Cheng to James J. Li, Ph.D., Scientific 

Review Officer, Center for Scientific 

Review, National Institutes of Health, 

6701 Rockledge Drive, Room 5148, MSC 

7849, Bethesda, MD. The meeting dates, 

times, and meeting location remain the 

same. The meeting is closed to the 

public. 

Dated: February 8, 2022. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–03054 Filed 2–11–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the National Cancer Institute 

Council of Research Advocates. 

The meeting will be held as a virtual 

meeting and is open to the public. 

Individuals who plan to view the virtual 

meeting and need special assistance or 

other reasonable accommodations to 

view the meeting, should notify the 

Contact Person listed below in advance 

of the meeting. The meeting will be 

videocast and can be accessed from the 

NIH Videocasting and Podcasting 

website (http://videocast.nih.gov). 

Name of Committee: National Cancer 

Institute Council of Research Advocates. 

Date: March 9, 2022. 

Time: 12:00 p.m. to 4:15 p.m. 

Agenda: Welcome and Chairman’s 

Remarks, NCI Updates, Legislative Update, 

and Director’s Update. 

Place: National Institutes of Health, 9000 

Rockville Pike, Bethesda, MD 20892 (Virtual 

Meeting). 


jspears on DSK121TN23PROD with NOTICES1